Emerging pro-drug and nano-drug strategies for gemcitabine-based cancer therapy

Gemcitabine has been extensively applied in treating various solid tumors. Nonetheless, the clinical performance of gemcitabine is severely restricted by its unsatisfactory pharmacokinetic parameters and easy deactivation mainly because of its rapid deamination, deficiencies in deoxycytidine kinase...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Haijie, Li, Su, Zhong, Yueyang, Huang, Yue, Wang, Kai, Jin, Qiao, Ji, Jian, Yao, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shenyang Pharmaceutical University 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888143/
https://www.ncbi.nlm.nih.gov/pubmed/35261643
http://dx.doi.org/10.1016/j.ajps.2021.06.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888143/
https://www.ncbi.nlm.nih.gov/pubmed/35261643
http://dx.doi.org/10.1016/j.ajps.2021.06.001

Ejemplares similares